Foundry Healthcare Return on Equity Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 35.88% |
2JNJ | JOHNSON & JOHNSON | Healthcare | $609.12B | 19.68% |
3AMGN | AMGEN INC | Healthcare | $197.69B | 6.39% |
4GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 5.39% |
5BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 4.01% |
6VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 3.98% |
7COR | CENCORA INC | Healthcare | $59.91B | 1.94% |
8IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 1.45% |
9TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 1.21% |
10A | AGILENT TECHNOLOGIES INC | Healthcare | $37.13B | 1.20% |
11ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 1.15% |
12IQV | IQVIA HOLDINGS INC | Healthcare | $34.42B | 1.11% |
13ZTS | ZOETIS INC | Healthcare | $32.10B | 1.04% |
14DXCM | DEXCOM INC | Healthcare | $29.58B | 0.96% |
15RMD | RESMED INC | Healthcare | $28.86B | 0.93% |
16GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $28.69B | 0.93% |
17ILMN | ILLUMINA INC | Healthcare | $28.24B | 0.91% |
18WST | WEST PHARMACEUTICAL SERVICES INC | Healthcare | $25.31B | 0.82% |
19INCY | INCYTE CORP | Healthcare | $23.42B | 0.76% |
20UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.73% |
21GH | GUARDANT HEALTH INC | Healthcare | $20.67B | 0.67% |
22NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.56% |
23THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 0.54% |
24BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.94B | 0.52% |
25MEDP | MEDPACE HOLDINGS INC | Healthcare | $15.36B | 0.50% |
26SOLV | SOLVENTUM CORP | Healthcare | $14.08B | 0.45% |
27EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.45% |
28PODD | INSULET CORP | Healthcare | $11.36B | 0.37% |
29EHC | ENCOMPASS HEALTH CORP | Healthcare | $11.13B | 0.36% |
30KRYS | KRYSTAL BIOTECH INC | Healthcare | $10.46B | 0.34% |
31CYTK | CYTOKINETICS INC | Healthcare | $9.98B | 0.32% |
32HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.30% |
33UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $9.15B | 0.30% |
34TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 0.27% |
35IBRX | IMMUNITYBIO INC | Healthcare | $8.04B | 0.26% |
36LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 0.23% |
37LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 0.23% |
38CHE | CHEMED CORP | Healthcare | $6.77B | 0.22% |
39PTCT | PTC THERAPEUTICS INC | Healthcare | $6.52B | 0.21% |
40SHC | SOTERA HEALTH CO | Healthcare | $5.06B | 0.16% |
41ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.14% |
42CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $4.04B | 0.13% |
43DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.13% |
44CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.12% |
45BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $3.58B | 0.12% |
46OGN | ORGANON & CO | Healthcare | $3.55B | 0.11% |
47RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 0.09% |
48GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $2.57B | 0.08% |
49TMDX | TRANSMEDICS GROUP INC | Healthcare | $2.56B | 0.08% |
50BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.08% |
51MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.15B | 0.07% |
52HTFL | HEARTFLOW INC | Healthcare | $2.15B | 0.07% |
53AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.11B | 0.07% |
54AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.07% |
55ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.07% |
56URGN | UROGEN PHARMA LTD | Healthcare | $1.96B | 0.06% |
57ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.05% |
58INVA | INNOVIVA INC | Healthcare | $1.60B | 0.05% |
59XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $1.52B | 0.05% |
60INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.05% |
61PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.04% |
62NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.04% |
63IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.04% |
64COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.04% |
65MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.04% |
66NUTX | NUTEX HEALTH INC | Healthcare | $1.12B | 0.04% |
67VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.03% |
68TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.03% |
69PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $873M | 0.03% |
70ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $755M | 0.02% |
71RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.02% |
72CRMD | CORMEDIX INC | Healthcare | $661M | 0.02% |
73TOI | ONCOLOGY INSTITUTE INC | Healthcare | $535M | 0.02% |
74CTEV | CLARITEV CORP | Healthcare | $518M | 0.02% |
75XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.02% |
76NRC | NRC HEALTH | Healthcare | $491M | 0.02% |
77PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.01% |
78ABEO | ABEONA THERAPEUTICS INC | Healthcare | $399M | 0.01% |
79STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.01% |
80EOLS | EVOLUS INC | Healthcare | $377M | 0.01% |
81ELMD | ELECTROMED INC | Healthcare | $349M | 0.01% |
82CV | CAPSOVISION INC | Healthcare | $335M | 0.01% |
83FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.01% |
84QTTB | Q32 BIO INC | Healthcare | $255M | 0.01% |
85SRZN | SURROZEN INC | Healthcare | $255M | 0.01% |
86RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.01% |
87KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.01% |
88PDEX | PRO DEX INC | Healthcare | $183M | 0.01% |
89OWLT | OWLET INC | Healthcare | $162M | 0.01% |
90RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.01% |
91PIII | P3 HEALTH PARTNERS INC | Healthcare | $78M | 0.00% |
92ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.00% |
93CLNN | CLENE INC | Healthcare | $76M | 0.00% |
94SCLX | SCILEX HOLDING CO | Healthcare | $72M | 0.00% |
95INKT | MINK THERAPEUTICS INC | Healthcare | $53M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $3.09T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 65% toward Growth. +3% unclassified (27 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual52.7%Margin-22.3%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual35.9%Margin-10.9%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 34.7% | -2.5% |
| 3 yearsp.a. | 10.5% | -11.2% |
| 5 yearsp.a. | 7.4% | -5.1% |
| 10 yearsp.a. | 10.2% | -4.7% |
| Since inceptionp.a. | 7.9% | -11.2% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 7.7% | -1.9% |
| 2025 | 14.7% | -23.7% |
| 2024 | 4.5% | -5.6% |
| 2023 | 3.9% | -6.5% |
| 2022 | -1.5% | -0.5% |
| 2021 | 25.9% | 18.8% |
| 2020 | 13.6% | -6.2% |
| 2019 | 15.7% | -21.0% |
| 2018 | 4.5% | 21.8% |
| 2017 | 23.2% | -6.0% |
| 2016 | -0.8% | 5.7% |
| 2015 | 4.8% | -7.9% |
| 2014 | 24.6% | -13.7% |
| 2013 | 41.0% | -11.0% |
| 2012 | 17.9% | -25.6% |
| 2011 | 10.9% | 17.7% |
| 2010 | 2.9% | -6.2% |
| 2009 | 18.9% | -3.0% |
| 2008 | -21.5% | 7.5% |
| 2007 | 6.7% | 10.4% |
| 2006 | 6.0% | 1.4% |
| 2005 | 5.4% | 16.4% |
| 2004 | 4.4% | 9.2% |
| 2003 | 12.4% | -33.6% |
| 2002 | -19.5% | 41.5% |
| 2001 | -13.2% | 16.9% |
| 2000 | 33.4% | -84.5% |
| 1999 | -4.3% | -63.3% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Return on Equity Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Return on Equity signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.